Novartis is further bolstering its preclinical pipeline and continuing its hunt for a Xolair successor, nailing down a ...
Japan’s Kyorin Pharmaceutical has entered into a global license agreement with Swiss pharma giant Novartis relating to ...
Kyorin Pharmaceutical Co. Ltd. has out-licensed its preclinical candidate, KRP-M223, and its back-up compounds to Novartis Pharma AG in a deal worth up to $777.5 million. Under the terms, Novartis ...
Kyorin Pharma has signed a deal with digital health firm Hyfe to develop a digital therapeutic (DTx) for people with chronic ...
Hosted on MSN2mon
KYORIN Strikes Deal with Bayer for OSA TreatmentKYORIN Pharmaceutical Co.,Ltd. (JP:4569) has released an update. Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest ...
DELRAY BEACH, Fla., Feb. 18, 2025 /PRNewswire/ -- Cyrano Therapeutics, Inc., a clinical-stage regenerative medicine company pioneering the development of treatments for smell loss, announced ...
The U.K has released a huge repository of children’s genomic data after sequencing blood samples from three large cohorts recruited at birth and followed across three decades. The power of the data is ...
Under this agreement, KYORIN obtains an option for the license of the right to develop and commercialize CYR-064 in Japan and will pay an option fee to Cyrano. Upon exercising the option and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback